Coherus Biosciences ( (CHRS) ) has released its Q2 earnings. Here is a breakdown of the information Coherus Biosciences presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Coherus Oncology is a commercial-stage oncology company focused on developing innovative cancer treatments, with a proprietary pipeline that includes LOQTORZI, a PD-1 inhibitor, and other promising candidates targeting various solid tumors. In its second-quarter 2025 earnings report, Coherus Oncology announced a significant 36% increase in net revenue for LOQTORZI, reaching $10 million, driven by increased patient demand and inventory restocking. The company also highlighted its strong cash position of $238 million, providing a runway through 2026 to support its ongoing clinical programs. Key financial metrics included a net loss from continuing operations of $44.9 million, an improvement from the previous year’s loss, and a substantial net income from discontinued operations due to the UDENYCA divestiture. Coherus is advancing its clinical pipeline with CHS-114 and casdozokitug, with data readouts expected in 2026, and aims to expand LOQTORZI’s market potential through strategic partnerships and label expansions. Looking ahead, Coherus remains focused on maximizing LOQTORZI’s potential and advancing its pipeline, with management optimistic about unlocking significant market opportunities and enhancing patient outcomes.